Metabolic and toxicological considerations for obsessive–compulsive disorder drug therapy

Bibliography

• Stein DJ. Obsessive-compulsive disorder. Lancet 2002;360:397-405
   PubMed Web of Science ®Google Scholar
• Hollander E. Obsessive–compulsive disorder: the hidden epidemic. J Clin Psychiatry 1997;58(Suppl 12):3-6
   PubMedGoogle Scholar
• Bebbington PE. Epidemiology of obsessive-compulsive disorder. Br J Psychiatry Suppl 1998;35:2-6
   PubMedGoogle Scholar
• Fernandez-Cordoba E, Lopez-Ibor Aliño J. La monoclomipramina en enfermos psiquiatricos resistentes a ostros tratamientos. Acta Luso Esp Neurol Psiquiatr Cienc Afines 1967;26:119-47
   Google Scholar
• Stein DJ, Hollander E. Serotonin specific re-uptake inhibitors in obsessive–compulsive disorder and related disorders. In: Feighner JP, Boyer WF, editors. Selective serotonin reuptake inhibitors. 2nd edition. Wiley, Chichester; 1996. p. 135-53
   Google Scholar
• Greist JH, Jefferson JW, Kobak KA, et al. Efficacy and tolerability of serotonin transport inhibitors in obsessive–compulsive disorder: a meta-analysis. Arch Gen Psychiatry 1995;52:53-60
   PubMed Web of Science ®Google Scholar
• Piccinelli M, Pini S, Bellantuono C, et al. Efficacy of drug treatment in obsessive–compulsive disorder: a meta-analytic review. Br J Psychiatry 1995;166:424-43
   PubMed Web of Science ®Google Scholar
• Ravizza L, Barzega G, Bellino S, et al. Drug treatment of obsessive–compulsive disorder: long-term trial with clomipramine and selective serotonin reuptake inhibitors. Psychopharmacol Bull 1996;32:167-73
   PubMed Web of Science ®Google Scholar
• Stein DJ, Spandaccini E, Hollander E. Meta-analysis of pharmacotherapy trials for obsessive–compulsive disorder. Int Clin Psychopharmacol 1995;10:11-18
   PubMed Web of Science ®Google Scholar
• Pigott TA, Pato MT, Bernstein SE, et al. Controlled comparisons of clomipramine and fluoxetine in the treatment of obsessive–compulsive disorder. Arch Gen Psychiatry 1990;47:926-32
   PubMed Web of Science ®Google Scholar
• Tamini RR, Mavissakalian MR, Jones V, et al. Clomipramine versus fluvoxamine in obsessive–compulsive disorder. Ann Clin Psychiatry 1991;3:275-9
   Google Scholar
• Leonard HL. New developments in the treatment of obsessive–compulsive disorder. J Clin Psychiatry 1997;58(Suppl 14):39-45
   PubMed Web of Science ®Google Scholar
• Pato MT, Zohar-Kadouch R, Zohar J, et al. Return of symptoms after discontinuation of clomipramine in patients with obsessive–compulsive disorder. Am J Psychiatry 1988;145:1521-5
   PubMed Web of Science ®Google Scholar
• Pato MT, Murphy DL, DeVane CL. Sustained plasma concentrations of fluoxetine and/or norfluoxetine for eight weeks after fluoxetine discontinuation. J Clin Psychopharmacol 1991;11:224-5
   PubMed Web of Science ®Google Scholar
• McDougle CJ, Goodman WK, Leckman JF, et al. The psychopharmacology of obsessive-compulsive disorder: implications for treatment and pathogenesis. Psychiatr Clin North Am 1993;16:749-66
   PubMed Web of Science ®Google Scholar
• Dell'Osso B, Nestadt G, Allen A, et al. Serotonin-norepinephrine reuptake inhibitors in the treatment of obsessive-compulsive disorder: a critical review. J Clin Psychiatry 2006;67:600-10
   PubMed Web of Science ®Google Scholar
• Sansone RA, Sansone LA. SNRIs Pharmacological alternatives for the treatment of obsessive compulsive disorder? Innov Clin Neurosci 2011;8:10-14
   Google Scholar
• Ravizza L, Barzega G, Bellino S, et al. Drug treatment of obsessive compulsive disorder (OCD): long-term trial with clomipramine and selective serotonin reuptake inhibitors (SSRIs). Psychopharmacol Bull 1996;32:167-73
   PubMed Web of Science ®Google Scholar
• Marazziti D, Golia F, Consoli G, et al. Effectiveness of long-term augmentation with citalopram to clomipramine in treatment-resistant OCD patients. CNS Spectr 2008;13:971-6
   PubMed Web of Science ®Google Scholar
• Bandelow B, Zohar J, Hollander E, et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive-compulsive and post-traumatic stress disorders first revision. W J Biol Psychiatry 2008;9:248-312
   PubMed Web of Science ®Google Scholar
• Stein DJ, Koen N, Fineberg N, et al. A 2012 evidence-based algorithm for the pharmacotherapy for obsessive-compulsive disorder. Curr Psychiatry Rep 2012;4:211-19
   Google Scholar
• Maher AR, Theodore G. Summary of the comparative effectiveness review on off-label use of atypical antipsychotics. J Manag Care Pharm 2012;18(5 Suppl B):1-20
   PubMedGoogle Scholar
• Pittenger C, Bloch MH, Willams K. Glutamate abnormalities in obsessive compulsive disorder: neurobiology, pathophysiology and treatment. Pharmacol Ther 2011;132:314-32
   PubMed Web of Science ®Google Scholar
• Baumann P. Pharmacokinetic-pharmacodynamic relationship of the selective serotonin reuptake inhibitors. Clin Pharmacokinet 1996;31:444-69
   PubMed Web of Science ®Google Scholar
• O'Donnell JM, Shelton RC. Drug therapy of depression and anxiety disorders. In: Brunton LL, Chabner BA, Bjorn K, editors. Goodman & Gilman's the pharmacological basis of therapeutics. 12th edition. The McGraw-Hill Companies, Inc, New York; 2011. p. 397-415
   Google Scholar
• Targownik LE, Bolton JM, Metge CJ, et al. Selective serotonin reuptake inhibitors are associated with a modest increase in the risk of upper gastrointestinal bleeding. Am J Gastroenterol 2009;104:1475-82
   PubMed Web of Science ®Google Scholar
• British National Formulary 61. 64th edition. Pharmaceutical Press, London; March 2012
   Google Scholar
• Schneeweiss S, Patrick AR, Solomon DH, et al. Comparative safety of antidepressant agents for children and adolescents regarding suicidal acts. Pediatrics 2010;125:876-88
   PubMed Web of Science ®Google Scholar
• Bronstein AC, Spyker DA, Cantilena LR. Jr, et al. 2009 annual report of the American association of poison control centers' national poison data system (NPDS): 27th annual report. Clin Toxicol (Phila) 2010;48:979-1178
   PubMed Web of Science ®Google Scholar
• Nelson LS, Erdman AR, Booze LL, et al. Selective serotonin reuptake inhibitor poisoning: an evidence-based consensus guideline for out-of-hospital management. Clin Toxicol (Phila) 2007;45:315-22
   PubMed Web of Science ®Google Scholar
• Warden SJ, Bliziotes MM, Wiren KM, et al. Neural regulation of bone and the skeletal effects of serotonin (5-hydroxytryptamine). Mol Cell Endocrinol 2005;242:1-9
   PubMed Web of Science ®Google Scholar
• Chen F, Hahn TJ, Weintraub NT. Do SSRIs play a role in decreasing bone mineral density? J Am Med Dir Assoc 2012;13:413-17
   PubMed Web of Science ®Google Scholar
• Ziere G, Dieleman JP, van der Cammen TJ, et al. Selective serotonin reuptake inhibiting antidepressants are associated with an increased risk of nonvertebral fractures. J Clin Psychopharmacol 2008;28:411-17
   PubMed Web of Science ®Google Scholar
• FDA Drug Safety Communication: selective serotonin reuptake inhibitor (SSRI) antidepressant use during pregnancy and reports of a rare heart and lung condition in newborn babies. Available from: http://www.fda.gov/drugs/drugsafety/ucm283375.htm
   Google Scholar
• Hiemke C, Haertter S. Pharmacokinetics of selective serotonin reuptake inhibitors. Pharmacol Ther 2000;85:11-28
   PubMed Web of Science ®Google Scholar
• Wenzel-Seifert K, Wittman M, Haen E. QTc prolongation by psychotropic drugs and the risk of torsade de pointes. Dtsch Arztebl Int 2011;108:687-93
   PubMed Web of Science ®Google Scholar
• Targownik LE, Bolton JM, Metge CJ, et al. Selective serotonin reuptake inhibitors are associated with a modest increase in the risk of upper gastrointestinal bleeding. Am J Gastroenterol 2009;104:1475-82
   PubMed Web of Science ®Google Scholar
• ACOG Committee on Obstetric Practice. ACOG Committee Opinion No. 354. Treatment with selective serotonin reuptake inhibitors during pregnancy. Obstet Gynecol 2006;108:1601-3
   PubMedGoogle Scholar
• Berle JØ, Spigset O. Antidepressant use during breastfeeding. Curr Womens Health Rev 2011;7(1):28-34
   PubMedGoogle Scholar
• Physicians' desk reference. 66th edition. PDR network, New Jersey; 2012
   Google Scholar
• Flanagan RJ. Fatal toxicity of drugs used in psychiatry. Hum Psychopharmacol 2008;23:43-51
   PubMed Web of Science ®Google Scholar
• Kelly CA, Dhaun N, Laing WJ, et al. Comparative toxicity citalopram and the newer antidepressants after overdose. Clin Toxicol 2005;42:67-71
   Web of Science ®Google Scholar
• White N, Litovitz T, Clancy C. Suicidal antidepressant overdose: a comparative analysis by antidepressant type. J Med Toxicol 2008;4:238-50
   PubMedGoogle Scholar
• Hayes BD, Klein-Schwartz W, Clark RF, et al. Comparison of toxicity of acute overdoses with citalopram and escitalopram. J Emerg Med 2010;39:44-8
   PubMed Web of Science ®Google Scholar
• Hawton K, Bergen H, Simkin S, et al. Toxicity of antidepressants: rates of suicide relative to prescribing and non-fatal overdose. Br J Psychiatry 2010;196:354-8
   PubMed Web of Science ®Google Scholar
• FDA drug safety communication: revised recommendation for Celexa (citalopram hydrobromide) related to a potential risk of abnormal heart rhythms with high doses. Available from: http://www.fda.gov/drugs/drugsafety/ucm297391.htm
   Google Scholar
• Forrester MB. Escitalopram ingestions reported to Texas poison control centers, 2002-2005. Hum Exp Toxicol 2004;26:473-82
   Google Scholar
• Abudy A, Juven-Wetzler A, Zohar A. Pharmacological management of treatment-resistant obsessive-compulsive disorder. CNS Drugs 2011;25:585-96
   PubMed Web of Science ®Google Scholar
• van Gorp F, Whyte IM, Isbister GK. Clinical and ECG effects of escitalopram overdose. Ann Emerg Med 2009;54:404-8
   PubMed Web of Science ®Google Scholar
• Mamiya K, Kojima K, Yukawa E, et al. Phenytoin intoxication induced by fluvoxamine. Ther Drug Monit 2001;23:75-7
   PubMed Web of Science ®Google Scholar
• Fritze J, Unsorg B, Lanczik M. Interaction between carbamazepine and fluvoxamine. Acta Psychiatr Scand 1991;84:583-4
   PubMed Web of Science ®Google Scholar
• Garnier R, Azoyan P, Chataigner D, et al. Acute fluvoxamine poisoning. J Int Med Res 1993;21:197-208
   PubMed Web of Science ®Google Scholar
• Available from: http://www.drugs.com/pro/anafranil.html
   Google Scholar
• De Carvalho SC, Marcourakis T, Artes R, et al. Memory performance in panic disorder patients after chronic use of clomipramine. J Psychopharmacol 2002;16:220-6
   PubMed Web of Science ®Google Scholar
• Dell'Osso B, Mundo E, Marazziti E, et al. Switching from serotonin reuptake inhibitors to duloxetine in patients with resistant obsessive-compulsive disorder: a case series. J Psychopharmacol 2008;22:210-13
   PubMed Web of Science ®Google Scholar
• Available from: http://www.drugs.com/pro/venlafaxine.html
   Google Scholar
• Whyte IM, Dawson AH, Buckley NA. Relative toxicity of venlafaxine and serotonin specific reuptake inhibitors in overdose compared to tricyclic antidepressants. QJM 2003;96:369-74
   PubMed Web of Science ®Google Scholar
• Khalifa M, Deleau P, Turgeon J. Mechanism of sodium channel block in guinea pig ventricular myocytes. J Pharmacol EXP Ther 1999;291:280-4
   PubMed Web of Science ®Google Scholar
• Bosse GM, Spiller HA, Collins AM. A fatal case of venlafaxine overdose. J Med Toxicol 2008;4:18-20
   PubMedGoogle Scholar
• Prasko J, Latalova K, Grambal A, et al. Off-label use of second generation antipsychotics in anxiety disorders and obsessive compulsive disorder. Act Nerv Super Rediviva 2010;52:229-40
   Google Scholar
• Bloch MH, Landeros-Weisenberger A, Kelmedi B, et al. A systematic review: antipsychotic augmentation with treatment-refractory obsessive-compulsive disorder. Mol Psychiatry 2006;11:622-32
   PubMed Web of Science ®Google Scholar
• Ipser JC, Carey P, Dhansay Y, et al. Pharmacotherapy augmentation strategies in treatment resistant anxiety disorders. Cochrane Database Syst Rev 2006;CD005473
   Google Scholar
• Fineberg NA, Gale TM, Sivakumaran T. A review of antipsychotics in the treatment of obsessive compulsive disorder. J Psychopharmacol 2006;20:97-103
   PubMed Web of Science ®Google Scholar
• Skapinakis P, Papatheodorou T, Mavreas V. Antipsychotic augmentation of serotonergic antidepressants in treatment-resistant obsessive-compulsive disorder: a meta-analysis of the randomized controlled trials. Eur Neuropsychopharmacol 2007;17:79-93
   PubMed Web of Science ®Google Scholar
• Kellner M. Drug treatment of obsessive-compulsive disorder. Dialogues Clin Neurosci 2010;12:187-97
   PubMedGoogle Scholar
• Dold M, Aigner M, Lanzenberger R, et al. Efficacy of antipsychotic augmentation therapy in treatment-resistant obsessive-compulsive disorder: a meta-analysis of double-blind, randomized placebo-controlled trials. Fortschr Neurol Psyhiatr 2011;79:453-66
   PubMed Web of Science ®Google Scholar
• Vasile D, Vasiliu O, Mangalagiu AG, et al. Augmentation strategies in selective serotonin reuptake inhibitors resistant obsessive-compulsive disorder: a systematic literature review. Ther Pharmacol Clin Toxicol 2011;15:83-92
   Google Scholar
• Meyer JM. Pharmacotherapy of psychosis and mania. In: Brunton LL, Chabner BA, Bjorn K, editors. Goodman & Gilman's the pharmacological basis of therapeutics. 12th edition. The McGraw-Hill Companies, Inc, New York; 2011. p. 417-55
   Google Scholar
• Available from: http://www.drugs.com/pro/risperidone.html
   Google Scholar
• Weiden PJ. EPS profiles: the atypical antipsychotics are not all the same. J Psychiatr Pract 2007;13:13-24
   PubMedGoogle Scholar
• Tan HH, Hope J, Heard K. A systematic review of cardiovascular effects after atypical antipsychotic medication overdose. Am J Emerg Med 2009;27:607-16
   PubMed Web of Science ®Google Scholar
• Novick D, Haro JM, Perrin E, et al. Tolerability of outpatient antipsychotic treatment: 36-month results from the European schizophrenia outpatient health outcomes (SOHO) study. Eur Neuropsychopharmacol 2009;19:542-50
   PubMed Web of Science ®Google Scholar
• Available from: http://www.drugs.com/pro/seroquel.html
   Google Scholar
• Stephani T, Trenkwalder C. Rhabdomyolysis after low dose quetiapine in a patient with Parkinson's disease drug-induced psychosis: a case report. Mov Disord 2010;25:790-1
   PubMed Web of Science ®Google Scholar
• Dickmann JR, Dickmann LM. An uncommonly recognized cause of rhabdomyolysis after quetiapine intoxication. Am J Emerg Med 2010;28:1060.e1-2
   PubMedGoogle Scholar
• Eyer F, Pfab R, Felgenhauer N, et al. Clinical and analytical features of severe suicidal quetiapine overdoses: a retrospective cohort study. Clin Toxicol 2011;49:846-53
   PubMed Web of Science ®Google Scholar
• Kumlien E, Lundberg PO. Seizure risk associated with neuroactive drugs: data from the WHO adverse drug reactions database. Seizure 2010;19:69-73
   PubMed Web of Science ®Google Scholar
• Ngo A, Ciranni M, Olson KR. Acute quetiapine overdose in adults: a 5-year retrospective case series. Ann Emerg Med 2008;52:541-7
   PubMed Web of Science ®Google Scholar
• Ciranni MA, Kearney TE, Olson KR. Comparing acute toxicity of first- and second-generation antipsychotic drugs: a 10 year, retrospective cohort study. J Clin Psychiatry 2009;70:122-9
   PubMed Web of Science ®Google Scholar
• Anita SX, Sholevar EH, Baron DA. Overdoses and ingestions of second-generation antipsychotics in children and adolescents. J Child Adolesc Psychopharmacol 2005;15:970-85
   PubMed Web of Science ®Google Scholar
• Available from: http://www.drugs.com/pro/zyprexa.html
   Google Scholar
• Rabinowitz J, Brauch Y, Barak Y. High dose escitalopram for the treatment of obsessive-compulsive disorder. Int Clin Psychopharmacol 2008;23:49-53
   PubMed Web of Science ®Google Scholar
• Zohar J. Escitalopram in the treatment of obsessive-compulsive disorder. Expert Rev Neurother 2008;8:339-49
   PubMedGoogle Scholar
• Ninan PT, Koran LM, Kiev A, et al. High dose sertraline strategy for nonresponders to acute treatment of obsessive-compulsive disorder: a multicenter double-blind trial. J Clin Psychiatry 2006;67:15-22
   PubMed Web of Science ®Google Scholar
• Serretti A, Mandelli L. Antidepressants and body weight: a comprehensive review and meta-analysis. J Clin Psychiatry 2010;71:1259-72
   PubMed Web of Science ®Google Scholar